Trial record 1 of 1 for:    aveo AND taurus
Previous Study | Return to List | Next Study

A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma (TAURUS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01673386
Recruitment Status : Completed
First Posted : August 28, 2012
Last Update Posted : June 23, 2015
Astellas Pharma Inc
Information provided by (Responsible Party):
AVEO Pharmaceuticals, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : January 2014
  Actual Study Completion Date : January 2014